Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06590545
What this trial is testing

Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis

Who this might be right for
ANCA-IgG-positive ANCA Associated Vasculitis
David Simon 8
Early research (Phase 1)UnknownNCT05270772
What this trial is testing

CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL

Who this might be right for
CD19+ Relapse/Refractory B-ALL
Chinese PLA General Hospital 9
Testing effectiveness (Phase 2)Study completedNCT01865617
What this trial is testing

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Who this might be right for
CD19-Positive Neoplastic Cells PresentRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic Leukemia+10 more
Fred Hutchinson Cancer Center 204
Early research (Phase 1)Ended earlyNCT03593109
What this trial is testing

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Second Affiliated Hospital of Xi'an Jiaotong University 1
Early research (Phase 1)Looking for participantsNCT04510051
What this trial is testing

CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

Who this might be right for
Malignant Brain NeoplasmRecurrent Malignant Brain NeoplasmRefractory Malignant Brain Neoplasm
City of Hope Medical Center 18
Very early researchNot Yet RecruitingNCT07330895
What this trial is testing

Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors

Who this might be right for
CD19+ Relapse/Refractory B-ALL
The First Affiliated Hospital with Nanjing Medical University 19
Early research (Phase 1)Looking for participantsNCT06287528
What this trial is testing

19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Philadelphia-Negative ALLPhiladelphia-Positive ALLRelapsed ALL, Adult+3 more
Memorial Sloan Kettering Cancer Center 18
Testing effectiveness (Phase 2)Looking for participantsNCT05334823
What this trial is testing

PCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Who this might be right for
Acute Lymphoblastic LeukemiaRelapsed Pediatric ALLRefractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd 100
Early research (Phase 1)UnknownNCT04215016
What this trial is testing

Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma

Who this might be right for
Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive
Fujian Medical University 18
Early research (Phase 1)Looking for participantsNCT06173518
What this trial is testing

CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B Cell Non-Hodgkin Lymphoma
Autolus Limited 30
Early research (Phase 1)Study completedNCT05665725
What this trial is testing

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
Timothy Voorhees 11
Early research (Phase 1)Looking for participantsNCT07620275
What this trial is testing

Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA

Who this might be right for
Multiple Myeloma
Chinese PLA General Hospital 9
Very early researchLooking for participantsNCT07429461
What this trial is testing

Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Who this might be right for
B-Cell Acute Lymphoblastic Leukemia
Zhejiang University 16
Early research (Phase 1)Active Not RecruitingNCT00840853
What this trial is testing

Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT

Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Chronic Lymphocytic Leukemia (CLL)Non Hodgkin's Lymphoma
Baylor College of Medicine 68
Very early researchNot Yet RecruitingNCT05779930
What this trial is testing

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseNon-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma Refractory+3 more
Nationwide Children's Hospital 12
Early research (Phase 1)Not Yet RecruitingNCT07316907
What this trial is testing

A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies

Who this might be right for
Hematologic MalignanciesLymphoma
YANRU WANG 12
Early research (Phase 1)Ended earlyNCT01493453
What this trial is testing

A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy

Who this might be right for
CD19 Positive Non-Hodgkin Lymphoma
The Christie NHS Foundation Trust 17
Very early researchUnknownNCT04011293
What this trial is testing

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

Who this might be right for
Relapsed or Refractory Hematological Malignancies
Shandong University 20
Not applicableUnknownNCT03488160
What this trial is testing

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

Who this might be right for
Lymphoma
Sinobioway Cell Therapy Co., Ltd. 6
Early research (Phase 1)Active Not RecruitingNCT03233854
What this trial is testing

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Who this might be right for
B Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual Disease+1 more
Stanford University 56
Next Page